TRUMP: Brings Down Prescription Drug Costs

Posted on May 12, 2025 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters and ChatGPT

***

***

President Trump to bring down prescription costs

In a Sunday post to Truth Social, President Trump signed an executive order at 9 am today to institute a most-favored-nation policy with pharmaceutical companies that he predicted could lower drug prices by 30% to 80%.

PBMs: https://medicalexecutivepost.com/2022/01/15/podcast-pharma-rebates-to-pbms/

“The United States will pay the same price as the Nation that pays the lowest price anywhere in the World,”

While Americans pay more for pharmaceuticals than any other country, Bloomberg reported that the American market fuels innovation and drives growth in the industry. Drug makers have pushed back on previous efforts to revamp the system in the US, saying it would make revenue evaporate and hinder the development of potentially lifesaving drugs.

WEIGHT LOSS: https://medicalexecutivepost.com/2023/10/24/weight-loss-drugs-for-kids-stocks-for-adults/

COMMENTS APPRECIATED

Like and Refer

***

***

Filed under: Ask a Doctor, Drugs and Pharma, Health Economics, Health Insurance, LifeStyle | Tagged: , , , , , , , , | Leave a comment »

RITE AID: Gets it Financially Wrong?

Posted on September 20, 2023 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

***

Last quarter, interest expense grew to $65 million from $48 million last year, contributing to Rite Aid reporting a net loss of $306.7 million despite sales of $5.6 billion. Management forecasts a net loss of between $650 million and $680 million for the full fiscal year 2024. Rite Aid’s losses leave it with little financial wiggle room to navigate two significant headwinds: a looming lawsuit and increasing losses from theft.

RISK MANAGEMENT: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

In March, for example, the Department of Justice filed a civil suit against Rite Aid, claiming pharmacists “repeatedly filled prescriptions for controlled substances with obvious red flags” and alleging it “intentionally deleted internal notes about suspicious prescribers.”

The lawsuit continues a string of high-profile cases brought against companies contributing to the spread of the opioid epidemic. Opioid drugmakers Purdue Pharma, Endo Pharmaceuticals, and Mallinckrodt have already declared bankruptcy because of lawsuits. Walgreens and CVS Health have inked opioid settlements valued at $5.7 billion and $4.9 billion over the past year.

How much Rite Aid would need to pay to settle its suit remains to be seen, but a billion-dollar price tag isn’t unfathomable, given Walgreens and CVS’ outcomes. 

CITE: https://www.r2library.com/Resource

***

COMMENTS APPRECIATED

Thank You

***

***

Filed under: "Doctors Only", Career Development, Drugs and Pharma, Events-Planner, Experts Invited, Funding Basics, Health Insurance, Health Law & Policy, Healthcare Finance, Investing | Tagged: , , , , , , , , , | Leave a comment »

NEW FDA DRUGS and Money

Posted on January 7, 2023 by Dr. David Edward Marcinko MBA MEd CMP™

By Staff Reporters

***

***

New medicines launched by US drug makers reached a median price of $222,003 last year, according to Reuters. These astronomical prices were fueled by three very-expensive gene therapies approved by the FDA. In fact, one of them, from Hemgenix, costs $3.5 million, making it the most expensive drug ever.

Congress did cap annual drug price increases via the Inflation Reduction Act, but that doesn’t cover the cost of new medications. Drug-makers, meanwhile, say the cost of their drugs doesn’t reflect what patients pay out-of-pocket for them.

MORE: https://www.msn.com/en-us/health/other/fda-approves-new-drug-lecanemab-that-appears-to-slow-early-mild-alzheimer-s/ar-AA163pDq?cvid=ee09eaf5a43f49bca0eb3a775051002e

***

COMMENTS APPRECIATED

Thank You

***

ORDER: https://www.amazon.com/Dictionary-Health-Insurance-Managed-Care/dp/0826149944/ref=sr_1_4?ie=UTF8&s=books&qid=1275315485&sr=1-4

***

Filed under: "Advisors Only", "Doctors Only", Drugs and Pharma, Ethics | Tagged: , , , , , , , , , | 1 Comment »

On Drug Reps as Future Dinosaurs

Posted on March 31, 2009 by Dr. David Edward Marcinko MBA MEd CMP™

Join Our Mailing List

More Doctors Closing Office Doors to Drug Salesmen

[By Staff Reporters]

56359286

According to Kevin B. O’Reilly, of the AMNews on 3/23/09, drug reps may soon become dinosaurs-of-sorts. And, the relationship between doctors and drug reps is cloudy, darkening and may never be the same again.

Changing Relationships

Pharmaceutical companies, battered by sluggish drug pipelines, the looming loss of blockbuster patented drugs, an economy in recession and scrutiny of their relationships with physicians; are re-examining the value of sending drug reps into doctors’ offices. Detailers are struggling to grab a shrinking slice of physicians’ valuable time, and attention, while adjusting to new drug industry rules banning freebies such as pens and notepads.

Declining Reputations

While most physicians still have positive views of detailers and drug-makers, those sentiments are cooling. And, the next-generation of medical students and future physicians may be another driver of this wave. About one in four physician’s works in a practice that refuses to see drug reps. Of doctors who do see reps, about 40% will meet with detailers only with scheduled appointments. The by-appointment-only figure jumped 23% during the last six months of 2008, according to a survey of more than 227,000 medical practices representing 640,000 physicians that was released in February.

***

 despair

***

Assessment

What is your practice policy on this issue? Are drug reps being replaced by webcasts, podcasts, IMs, text-messages, cell phone advertisements, direct-to-doctor [D2D] communications and/or some other new-wave social media or rich e-format? 

Channel Surfing the ME-P

Have you visited our other topic channels? Established to facilitate idea exchange and link our community together, the value of these topics is dependent upon your input. Please take a minute to visit. And, to prevent that annoying spam, we ask that you register. It is fast, free and secure.

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

Product DetailsProduct DetailsProduct Details

Filed under: "Doctors Only", Drugs and Pharma, Ethics, Managed Care, Practice Management | Tagged: , , , , , , , , , , , , | 13 Comments »